YUCAIPA, Calif., Jan. 15, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:ITEC) announced today that the Business Press has released a Special Report about Ingen Technologies and its Oxyview product last Sunday, January 11, 2009.
Carol Park, Reporter for the Riverside, California newspaper spent time researching Ingen and the new Oxyview product. "Carol did her research thoroughly and was enthused about the company, our management and our product line," stated Scott Sand, Chairman and CEO.
The Biz Press is a sister publication of The Press-Enterprise and is headquartered in Riverside. It's been around for more than 17 years.
For more information please visit:
About Ingen Technologies, Inc.
Ingen is an emerging medical device manufacturer within the $4 Billion respiratory market. Oxyview was released in late 2007 with a successful registration and classification with the Food and Drug Administration. OxyAlert is currently under FDA evaluation. The company continues to expand distribution of its respiratory products, and has recently gained momentum in OEM partnerships with larger respiratory equipment manufacturers. Oxyview has found sales channels in various industries that include medical, aviation, automotive, emergency response, military and government transportation.
The Ingen Technologies, Inc. logo is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.